Results 191 to 200 of about 5,659,298 (338)

Liquid biopsy epigenetics: establishing a molecular profile based on cell‐free DNA

Molecular Oncology, EarlyView.
Cell‐free DNA (cfDNA) fragments in plasma from cancer patients carry epigenetic signatures reflecting their cells of origin. These epigenetic features include DNA methylation, nucleosome modifications, and variations in fragmentation. This review describes the biological properties of each feature and explores optimal strategies for harnessing cfDNA ...
Christoffer Trier Maansson, Anders Lade Nielsen, Boe Sandahl Sorensen   +2 more
wiley   +1 more source

European Society for Medical Oncology (ESMO) Gastrointestinal Cancers congress 2025. [PDF]

Lancet Reg Health Eur
Nedic I.
europepmc   +1 more source

Eighteen Years of Medical Oncology in Morocco: A Bibliometric Evaluation. [PDF]

Cureus, 2023
Kaakoua M, Boufdil A, El Fadli M, Belbaraka R, Essadi I.   +4 more
europepmc   +1 more source

Medical Oncology [PDF]

, 2013
openaire   +1 more source

Intein‐based modular chimeric antigen receptor platform for specific CD19/CD20 co‐targeting

Molecular Oncology, EarlyView.
CARtein is a modular CAR platform that uses split inteins to splice antigen‐recognition modules onto a universal signaling backbone, enabling precise, scarless assembly without re‐engineering signaling domains. Deployed here against CD19 and CD20 in B‐cell malignancies, the design supports flexible multi‐antigen targeting to boost T‐cell activation and
Pablo Gonzalez‐Garcia, Noelia Moares, Wenjie Yi‐He, Rosa Luna‐Espejo, Ricardo Fernandez‐Cisnal, Javier Ocaña‐Cuesta, Juan P. Muñoz‐Miranda, Antonio Gabucio, Cecilia M. Fernandez‐Ponce, Francisco Garcia‐Cozar   +9 more
wiley   +1 more source

Supplementum 283: Abstracts of the Swiss Oncology & Hematology Congress (SOHC)

Swiss Medical Weekly
Swiss Society of Medical Oncology, Swiss Society of Hematology, Swiss Group for Clinical Cancer Research   +2 more
doaj   +1 more source

Implementing Ryan's Law on an Inpatient Medical Oncology Unit. [PDF]

Clin J Oncol Nurs
McKaig A, Varilla Ridad AR, Bell A, McParlane R, Quirch M.   +4 more
europepmc   +1 more source

First impressions: A prospective evaluation of patient-physician concordance and satisfaction following the initial medical oncology consultation. [PDF]

Cancer Med, 2023
Bach Y, Panov E, Espin-Garcia O, Chen E, Krzyzanowska M, O'Kane G, Moore M, Prince RM, Knox J, Grant R, Ma LX, Allen MJ, Eng L, Kosyachkova E, Megid TBC, Barron C, Wang X, Saltiel MP, Farooq ARR, Jang RW, Elimova E.   +20 more
europepmc   +1 more source

European Society for Medical Oncology (ESMO) position paper on supportive and palliative care

Annals of Oncology, 2018
K. Jordan, M. Aapro, S. Kaasa, S. Kaasa, S. Kaasa, C. Ripamonti, F. Scotté, F. Strasser, A. Young, E. Bruera, J. Herrstedt, D. Keefe, B. Laird, D. Walsh, J. Douillard, A. Cervantes   +15 more
semanticscholar   +1 more source

Improving PARP inhibitor efficacy in bladder cancer without genetic BRCAness by combination with PLX51107

Molecular Oncology, EarlyView.
Clinical trials on PARP inhibitors in urothelial carcinoma (UC) showed limited efficacy and a lack of predictive biomarkers. We propose SLFN5, SLFN11, and OAS1 as UC‐specific response predictors. We suggest Talazoparib as the better PARP inhibitor for UC than Olaparib.
Jutta Schmitz, Anna L. Bartkowiak, Michael Rose, Nora Kolks, Patrick Petzsch, Vandana Solanki, Anne Stoffel, Bianca Faßbender, Leandra Lepping, Julka Volkamer, Karl Köhrer, Marc Seifert, Tokameh Mahmoudi, Tahlita C. M. Zuiverloon, Günter Niegisch, Michèle J. Hoffmann   +15 more
wiley   +1 more source